<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572725</url>
  </required_header>
  <id_info>
    <org_study_id>2018/785</org_study_id>
    <nct_id>NCT03572725</nct_id>
  </id_info>
  <brief_title>Air Tamponade and Non-supine Positioning in Macular Hole Surgery.</brief_title>
  <official_title>Air Tamponade and Non-supine Positioning in Macular Hole Surgery. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trondheim University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized non-inferiority trial, where the macular hole
      closure rate with intraocular air tamponade is compared to the closure rate with gas
      tamponade.The patients are randomized to receive either air or gas (26% SF6) as intraocular
      tamponade, just prior to the intraocular flushing of the tamponade during the vitrectomy
      procedure. Postoperatively, the patients adhere to the nonsupine regimen for three days, and
      the tennis ball technique is used during sleep to enhance patients' positioning compliance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular hole closure verified on OCT</measure>
    <time_frame>2 - 8 weeks postoperatively</time_frame>
    <description>Macular hole closure verified on OCT after one macular hole intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Closure of macular holes ≤ 250 µm</measure>
    <time_frame>2 - 8 weeks postoperatively</time_frame>
    <description>Macular hole closure verified on OCT after one macular hole intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Closure of macular holes &gt;250 µm and ≤ 400 µm</measure>
    <time_frame>2 - 8 weeks postoperatively</time_frame>
    <description>Macular hole closure verified on OCT after one macular hole intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>First postoperative day</time_frame>
    <description>Standard procedure for assessment of intraocular pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>2 - 8 weeks postoperatively</time_frame>
    <description>Standard procedure for assessment of visual acuity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Macular Holes</condition>
  <arm_group>
    <arm_group_label>Gas tamponade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gas as intraocular tamponade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Air tamponade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Air as intraocular tamponade.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gas tamponade</intervention_name>
    <description>Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.</description>
    <arm_group_label>Gas tamponade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Air tamponade</intervention_name>
    <description>Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.</description>
    <arm_group_label>Air tamponade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary macular hole ≤ 400 μm

          -  Duration no more than 24 months

          -  Able to sign informed content

          -  Signed informed content

        Exclusion Criteria:

          -  Earlier vitreoretinal surgery in present eye

          -  Secondary macular holes caused by other conditions than vitreomacular traction

          -  Myopic macular hole, i.e. excessive myopia (more than -6 dioptres)

          -  Posttraumatic macular hole

          -  Macular holes secondary to retinal detachment or other retinal diseases

          -  Surgery under general anesthesia

          -  Visual acuity below 20/40 in fellow-eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard Forsaa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vegard Forsaa, PhD</last_name>
    <phone>48152212</phone>
    <phone_ext>+47</phone_ext>
    <email>vegard.forsaa@sus.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joergen Krohn, PhD</last_name>
      <email>jorgen.krohn@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Joergen Krohn, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paal Varhaug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Haugstad, MD</last_name>
      <email>UXARGS@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Marta Haugstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingar Stene-Johansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital, Department of Ophthalmology</name>
      <address>
        <city>Stavanger</city>
        <zip>4016</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vegard Forsaa, MD</last_name>
      <phone>+47 48152212</phone>
      <email>vegard.forsaa@sus.no</email>
    </contact>
    <investigator>
      <last_name>Vegard Forsaa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Birger Lindtjørn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian Fossen, MD</last_name>
      <email>kristian.fossen@unn.no</email>
    </contact>
    <investigator>
      <last_name>Kristian Fossen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dordi Austeng, PhD</last_name>
      <email>Dordi.Austeng@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Dordi Austeng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sammy Basit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Perforations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

